NEWS
Ashland, MA, March 13, 2025 – BioSurfaces, a leader in advanced nanofiber materials, and Morphocell Technologies, are pleased to announce a collaboration aimed at exploring the potential of BioSurfaces’ proprietary Bio-Spun™ material for therapeutic applications.
Montreal, QC, October 30, 2024 – Morphocell Technologies is thrilled to announce the appointment of Dr. Paul K. Wotton as an independent member of its Board of Directors.
Montreal, QC, August 5, 2024 – Morphocell Technologies welcomes Dr. Vincent Ling as its new Chief Business Officer.
Montreal, QC, May 2, 2024 – Morphocell Technologies is pleased to announce the appointment of Marc Courtois as a member of its Board of Directors, effective immediately.
Montreal, QC, May 2, 2024 – Morphocell Technologies is thrilled to announce the appointment of Didier Leconte as an independent member of its Board of Directors, effective immediately.
Montreal, QC, April 22, 2024 – Morphocell Technologies is proud to announce the appointment of Patrick Bedford as our new Vice President of Regulatory Affairs.
Laval, QC, April 4, 2024 - Morphocell Technologies proudly announces the closure of a US$40 million Series A financing round. This significant financial milestone, led by Genson Capital, is set to fuel the company’s groundbreaking journey towards a first-in-human clinical trial.
Montreal, QC, January 17, 2024 – Morphocell Technologies is thrilled to announce the appointment of Dr. Calley Hirsch as its new Vice President Preclinical Development.
Montreal, QC, July 24, 2023 – Morphocell Technologies is excited to announce the appointment of Dr. Panos Chrysanthopoulos as its new Chief Development Officer.
Morphocell will present its progress, platform and preclinical data at Biotech Showcase 2023, one of the most important investor conferences, in San Francisco, CA.
Morphocell Technologies announces the publication of an innovative, scalable method for generating high-quality liver cells from induced pluripotent stem cells.
The US Patent Office (USPTO) has granted Morphocell Technologies patent number US11096388 covering the use of its Encapsulated Liver Tissue as part of a Bioartificial Liver Device
Morphocell partners with CQDM and Takeda Pharmaceuticals to support the development of its ReLiver technology for the treatment of liver failure
Morphocell Technologies, CQDM and Takeda Pharmaceutical Company Limited, with support from the Stem Cell Network, came together to fund a $979,200 Quantum Leap project that will enable Morphocell to generate preclinical efficacy and safety data in large animals for ReLiver®ELT
Morphocell has been selected to deliver a company presentation at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled June 10-11 & 14-18, 2021.
Morphocell Technologies’ quest to transform the treatment of liver disease took another major step forward today with the announcement of new Stem Cell Network (SCN) funding for the Paganelli lab at Le Centre hospitalier universitaire Sainte-Justine.
The Morphocell team is gearing up for a busy and exciting 2020, starting with our participation at two can’t-miss conferences.
Stem cell commercialization expert Dr. Jennifer Moody appointed Chief Operating Officer beginning October 7th, 2019.
Morphocell Technologies Inc. held a successful pre-pre-Clinical Trial Application (CTA) meeting with Health Canada in August 2019.
Dr. Margaret Bywater Ekegärd is stepping down as Chief Executive Officer and President. She will continue as a member of the Board of Directors and assume a new role as a special adviser to Morphocell’s operations.
Morphocell Technologies signs exclusive license for the commercialisation of innovative stem cell-derived Encapsulated Liver Tissue technology.